Evidence map›Paper›PMID 33764701›Full record

ArticleRadiology and oncology2020

The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors.

Tomaz Smrkolj, Urska Cegovnik Primozic, Teja Fabjan, Sasa Sterpin, Josko Osredkar

Abstract readComparative StudyEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology and oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers-What Should a Urologist Really Know?International journal of environmental research and public health · 2022
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tomaz SmrkoljDepartment of Urology, Ljubljana University Medical Centre, Ljubljana, Slovenia.
Urska Cegovnik PrimozicClinical Institute of Clinical Chemistry and Biochemistry, Ljubljana University Medical Centre, Ljubljana, Slovenia.
Teja FabjanClinical Institute of Clinical Chemistry and Biochemistry, Ljubljana University Medical Centre, Ljubljana, Slovenia.
Sasa SterpinClinical Institute of Clinical Chemistry and Biochemistry, Ljubljana University Medical Centre, Ljubljana, Slovenia.
Josko OsredkarClinical Institute of Clinical Chemistry and Biochemistry, Ljubljana University Medical Centre, Ljubljana, Slovenia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCystoscopy in complement with urinary cytology represents the gold standard for the follow-up of patients with urinary bladder tumours. Xpert Bladder Cancer Monitor Test (XBC) is a novel mRNA-based urine test for bladder cancer surveillance. The aim of the study was to evaluate the performance of the XBC and voided urinary cytology (VUC) in the follow-up of bladder tumours. PATIENTS AND

methodsThe XBC was performed on stabilized voided urine and VUC was performed on urine samples. The results were compared to cystoscopic findings and histopathological results after transurethral resection of the bladder lesion.

resultsFor the prediction of malignant histopathological result sensitivity, the specificity and negative predictive value were 76.9%, 9 7.5% and 93.0% for the XBC and 38.4%, 9 7.5% and 83.3%, respectively for VUC. For the prediction of suspicious or positive cystoscopic finding sensitivity, the specificity and negative predictive value were 75.0%, 95.2%, and 93.0% respectively for the XBC and 41.7%, 97.6%, and 85.4% for VUC. The sensitivities for papilary urothelial neoplasms of low malignant potential (PUNLMP), low- and high-grade tumours were 0.0%, 66.7% an d 100.0% for the XBC and 0.0%, 66 .7% and 42.9%, respectively for VUC.

conclusionsThe XBC showed significantly higher overall sensitivity and negative predictive value than VUC and could be used to increase the recommended follow-up cystoscopy time intervals. Complementing the XBC and voided urinary cytology does not improve performance in comparison to the XBC alone.

Indexed as

AnnexinsArea Under CurveCarcinomaCorticotropin-Releasing HormoneCystoscopyFemaleFollow-Up StudiesHumansInsulin-Like Growth Factor IIMaleNeoplasm ProteinsPredictive Value of TestsProto-Oncogene Proteins c-ablReverse Transcriptase Polymerase Chain ReactionRNA, MessengerROC CurveABL1 protein, humanAnnexinsANXA10 protein, humanCorticotropin-Releasing HormoneIGF2 protein, humanInsulin-Like Growth Factor IINeoplasm ProteinsProto-Oncogene Proteins c-ablRNA, MessengerUPK1B protein, humanUroplakin Ibcystoscopyurinary bladder neoplasmvoided urinary cytologyXpert BC Monitor Test

Identifiers

PMID33764701
PMCPMC8042818

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.